193 related articles for article (PubMed ID: 33506318)
1. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
Yang J; Liu R; Ektare V; Stephens J; Shelbaya A
Appl Health Econ Health Policy; 2021 Jul; 19(4):605-618. PubMed ID: 33506318
[TBL] [Abstract][Full Text] [Related]
2. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
4. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
[No Abstract] [Full Text] [Related]
5. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
7. The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
Wallace K; Adamski K; Pai A; Rose D; Chawla A
Pharmacoeconomics; 2021 Feb; 39(2):231-241. PubMed ID: 33145712
[TBL] [Abstract][Full Text] [Related]
8. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
Baker CL; Ferrufino CP; Bruno M; Kowal S
Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
[TBL] [Abstract][Full Text] [Related]
9. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
[TBL] [Abstract][Full Text] [Related]
10. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract][Full Text] [Related]
11. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
12. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
13. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
[No Abstract] [Full Text] [Related]
14. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
[TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
17. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
Burudpakdee C; Shah A; Joish VN; Divers C; Yaldo A
Am Health Drug Benefits; 2014 Dec; 7(9):479-87. PubMed ID: 25610527
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data.
Yang J; Liu R; Granghaud A; Zaidi O; Stephens J
J Med Econ; 2021; 24(1):665-674. PubMed ID: 33904357
[TBL] [Abstract][Full Text] [Related]
19. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
20. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
